Compare STRIDES PHARMA SCIENCE with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs VENUS REMEDIES - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE VENUS REMEDIES STRIDES PHARMA SCIENCE/
VENUS REMEDIES
 
P/E (TTM) x 14.6 -1.0 - View Chart
P/BV x 0.9 0.1 1,253.5% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   VENUS REMEDIES
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
VENUS REMEDIES
Mar-18
STRIDES PHARMA SCIENCE/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,147126 911.0%   
Low Rs64261 1,050.7%   
Sales per share (Unadj.) Rs317.2301.8 105.1%  
Earnings per share (Unadj.) Rs7.8-24.9 -31.5%  
Cash flow per share (Unadj.) Rs25.12.5 984.7%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.3293.3 93.5%  
Shares outstanding (eoy) m89.5012.34 725.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.80.3 910.1%   
Avg P/E ratio x114.0-3.8 -3,033.0%  
P/CF ratio (eoy) x35.736.7 97.2%  
Price / Book Value ratio x3.30.3 1,023.1%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0581,154 6,938.7%   
No. of employees `0002.50.9 271.0%   
Total wages/salary Rs m4,341393 1,104.2%   
Avg. sales/employee Rs Th11,325.84,026.1 281.3%   
Avg. wages/employee Rs Th1,731.4425.0 407.4%   
Avg. net profit/employee Rs Th280.1-331.8 -84.4%   
INCOME DATA
Net Sales Rs m28,3943,724 762.4%  
Other income Rs m94123 4,180.4%   
Total revenues Rs m29,3343,747 783.0%   
Gross profit Rs m3,965395 1,004.4%  
Depreciation Rs m1,540338 455.3%   
Interest Rs m1,962354 553.9%   
Profit before tax Rs m1,403-275 -509.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m9732 307.9%   
Profit after tax Rs m702-307 -228.8%  
Gross profit margin %14.010.6 131.7%  
Effective tax rate %6.9-11.5 -60.4%   
Net profit margin %2.5-8.2 -30.0%  
BALANCE SHEET DATA
Current assets Rs m24,8362,638 941.6%   
Current liabilities Rs m18,9932,305 824.1%   
Net working cap to sales %20.68.9 230.1%  
Current ratio x1.31.1 114.3%  
Inventory Days Days71135 52.4%  
Debtors Days Days11346 244.8%  
Net fixed assets Rs m34,2894,871 704.0%   
Share capital Rs m895123 725.3%   
"Free" reserves Rs m23,6513,496 676.6%   
Net worth Rs m24,5463,619 678.2%   
Long term debt Rs m15,5131,374 1,128.7%   
Total assets Rs m65,4377,509 871.5%  
Interest coverage x1.70.2 769.2%   
Debt to equity ratio x0.60.4 166.4%  
Sales to assets ratio x0.40.5 87.5%   
Return on assets %4.10.6 645.0%  
Return on equity %2.9-8.5 -33.7%  
Return on capital %6.91.6 435.8%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m15,6970-   
Fx outflow Rs m735517 142.4%   
Net fx Rs m14,962-517 -2,896.7%   
CASH FLOW
From Operations Rs m1,871514 363.7%  
From Investments Rs m5,826-123 -4,732.7%  
From Financial Activity Rs m-10,157-387 2,623.8%  
Net Cashflow Rs m-2,6154 -62,259.3%  

Share Holding

Indian Promoters % 27.7 32.9 84.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 0.2 21,000.0%  
FIIs % 8.6 0.6 1,482.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 66.4 39.0%  
Shareholders   56,241 20,121 279.5%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   SHASUN PHARMA  WYETH LTD  GSK PHARMA  FULFORD INDIA  DR. REDDYS LAB  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

STRIDES PHARMA SCIENCE Surges by 5%; BSE HEALTHCARE Index Up 0.7% (Market Updates)

Oct 15, 2019 | Updated on Oct 15, 2019

STRIDES PHARMA SCIENCE share price has surged by 5% and its current market price is Rs 356. The BSE HEALTHCARE is up by 0.7%. The top gainers in the BSE HEALTHCARE Index is STRIDES PHARMA SCIENCE (up 5.0%). The top losers are ABBOTT INDIA (down 0.1%) and PIRAMAL ENTERPRISES (down 0.2%).

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 15, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS